# ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1)

Source: https://onco.cc/trials/zen-3694-abemaciclib-nut/  
OnCo record `zen-3694-abemaciclib-nut` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A chemotherapy-free combination for NUT carcinoma: a BET inhibitor with a CDK4/6 inhibitor, on the reasoning that both act on the MYC-driven growth programme the fusion switches on.

## Summary

BRD4-NUT keeps MYC and other growth genes switched on; BET inhibition alone gives short responses. This NCI phase 1 study adds abemaciclib, a CDK4/6 inhibitor, to ZEN003694 in patients with NUT carcinoma, advanced breast cancer and other solid tumours, to find a tolerable dose and look for activity. It is recruiting.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: owner-request
- Registry id: NCT05372640
- Phase: 1
- Setting: NUT carcinoma, advanced breast cancer and other solid tumours: BET inhibitor ZEN003694 with the CDK4/6 inhibitor abemaciclib; started August 2023, 45 planned
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT05372640: https://clinicaltrials.gov/study/NCT05372640

## Connected records

- cancers: [NUT carcinoma (midline carcinoma with NUTM1 rearrangement)](https://onco.cc/cancers/nut-carcinoma/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/)
- targets: [CDK4/6](https://onco.cc/targets/cdk4-6/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [ZEN-3694](https://onco.cc/drugs/zen-3694/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)

---
JSON: https://onco.cc/api/v1/entities/zen-3694-abemaciclib-nut.json